Biotrin Announces Agreement with BD Biosciences
News Mar 10, 2006
Biotrin has announced an agreement with BD Biosciences, a segment of BD (Becton, Dickinson and Company), for the distribution of Biotrin's biomarker range of products for the detection of early organ damage.
Under the terms of the distribution agreement, BD Biosciences has been appointed as world-wide distributor of the Biotrin Biomarkers product range to pharmaceutical companies, contract research organisations, universities and research centres.
"We believe this agreement will enable us to capitalize on the growing demand for our expanding biomarker product line and help achieve our goal of making Biotrin Biomarkers the number one choice for the detection of early organ damage," said Dr. Cormac G. Kilty, CEO of Biotrin.
"With the sales and marketing teams from Biotrin and BD Biosciences working together, we will expand the reach of this product line throughout the world."
Biotrin identifies and selects biomarkers of interest using proprietary HISTOMICS® technology.
Biotrin Biomarkers are designed to provide specific and quantitative information allowing researchers to determine the exact location and amount of damage an organ has undergone and to monitor the progression of damage, either as a result of disease or the administration of toxic compounds.
Under the agreement, BD Biosciences will sell the Biotrin Biomarkers product range throughout the world.
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE